Fidus Inv (NASDAQ:FDUS) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.49 by 4.08 percent. This is a 4.08 percent increase over earnings of $0.49 per share from the same period last year.
AN2 Therapeutics to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the
